We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Analysis of Antihypertensive Treatment Efficacy (ATACA)

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00767247
First Posted: October 7, 2008
Last Update Posted: December 3, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
Analysis of antihypertensive treatment efficacy.

Condition
Arterial Hypertension

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Analysis of Antihypertensive Treatment Efficacy

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Analysis of antihypertensive treatment efficacy. [ Time Frame: measurement BP: 3 visits for 3 month ]

Estimated Enrollment: 2000
Study Start Date: May 2008
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Male or female with arterial hypertension

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
outpatient clinics
Criteria

Inclusion Criteria:

  • arterial hypertension
  • intake of Atacand before study enrollment

Exclusion Criteria:

  • hypersensitivity to candesartan or any other ingredient of Atacand
  • liver function impairment and/or cholestasis
  • severe renal insufficiency (serum creatinine > 265 µmol/L)
  • Pregnant and lactating women
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00767247


Locations
Russian Federation
Research Site
Arhangelsk, Russian Federation
Research Site
Bryansk, Russian Federation
Research Site
Domodedovo, Russian Federation
Research Site
Dzerzhinsk, Russian Federation
Research Site
Ekaterinburg, Russian Federation
Research Site
Essentuki, Russian Federation
Research Site
Georgievsk, Russian Federation
Research Site
Irkutsk, Russian Federation
Research Site
Kazan, Russian Federation
Research Site
Samara, Russian Federation
Research Site
Severodvinsk, Russian Federation
Research Site
Vidnoe, Russian Federation
Research Site
Volgograd, Russian Federation
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Dmitry Zateyshchikov, MD, Prof Federal State Institution of Russian President's General Management Department
  More Information

Responsible Party: Andrey Strugovshchikov, Medical Director, Astra Zeneca, Russia
ClinicalTrials.gov Identifier: NCT00767247     History of Changes
Other Study ID Numbers: NIS-CRU-ATA-2008/1
First Submitted: October 6, 2008
First Posted: October 7, 2008
Last Update Posted: December 3, 2010
Last Verified: December 2010

Keywords provided by AstraZeneca:
Arterial Hypertension

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents